Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Aytu BioPharma reported fiscal 2026 Q4 net revenue of $16.1M, up 6.4% YoY. EXXUA, launched in Q3, generated $3.9M in Q4 revenue with 3,323 prescriptions. Full-year revenue was $57.6M, down 13.3% YoY. CEO Josh Disbrow highlighted EXXUA's growth and legacy portfolio stability. Cash balance was $26.3M at June 30, 2026.

Original reporting
Published Sep 22, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AYTU
Bullish
medium confidence
Mentioned
$AYTU
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$AYTUBullishMed
01

Why it matters

The earnings release provides the first public data on FY2026 performance, highlighting a narrowing loss and rapid prescription growth for EXXUA.

02

Market read

Microcap biotech earnings with a new product launch; may trigger short‑term trading activity.

03

What to watch

Potential reimbursement challenges and generic competition in the ADHD portfolio could pressure margins.

Relevance 6/10Novelty 7/10Timing: post‑quarter earnings release today

Background

Aytu BioPharma (Nasdaq: AYTU) focuses on CNS disorders and recently launched EXXUA for major depressive disorder.

Company-level read

Ticker impact

$AYTUBullishMedium confidence
Context

Aytu BioPharma released its FY2026 full year and Q4 operational and financial results, including net revenue of $16.1M for Q4 and a break-even net loss, marking the first public disclosure of these numbers.

Expected impact

Potential modest upside as investors digest improved loss profile and growth in EXXUA prescriptions.

Evidence & confidence

The company posted a narrower loss than the prior year and highlighted rapid adoption of its new product, which could attract buying interest in a low‑float microcap.

Market effects

Positive signal for CNS‑focused biotech sector as a new ADHD/MDD therapy shows early uptake.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

The modest revenue growth may not be sufficient to sustain long‑term profitability; high reliance on EXXUA could pose risk if adoption stalls.

Key entities

  • Josh Disbrow

    Chief Executive Officer of Aytu BioPharma, provided commentary on the EXXUA launch.

Related articles

$AYTUHighAI 9/10

Rosemont to acquire Aytu BioPharma for $2.70 per share

Rosemont Pharmaceuticals will acquire Aytu BioPharma (NASDAQ:AYTU) for $2.70 per share, a 41.1% premium over Aytu's 30-day average. The deal, approved by Aytu's board, is expected to close by late 2026. Aytu focuses on central nervous system disease treatments. Rosemont is backed by private equity firm Inflexion.

$AYTUHigh

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / Novemb

$AYTUMed

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi